SCHEMBL31728083

SCHEMBL31728083

[2H]C([2H])([2H])Oc1cc(Br)c2ncnc(N)c2c1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 1/20 0.35
▸ KDR P35968 9/20 0.33
▸ PIK3CD O00329 8/20 0.33
▸ ABL1 P00519 8/20 0.33
▸ EGFR P00533 8/20 0.33
▸ HCK P08631 8/20 0.33
▸ SRC P12931 8/20 0.33
▸ PIK3CA P42336 8/20 0.33
▸ PIK3CB P42338 8/20 0.33
▸ MTOR P42345 8/20 0.33
▸ PIK3CG P48736 8/20 0.33
▸ EPHB4 P54760 8/20 0.33
▸ PRKDC P78527 8/20 0.33
▸ PI4KB Q9UBF8 7/20 0.33
▸ LIMK1 P53667 3/20 0.33
▸ CDC7 O00311 2/20 0.33
▸ PLK4 O00444 2/20 0.33
▸ AURKA O14965 2/20 0.33
▸ ROCK2 O75116 2/20 0.33
▸ PIM1 P11309 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31728476 0.83 PDE5A (0.35) PDE5AKDRPIK3CDABL1EGFR
SCHEMBL31728053 0.72 PDE5A (0.44) PDE5AKDRPIK3CDABL1EGFR
SCHEMBL31729158 0.67 PIK3CD (0.37) KDRPIK3CDABL1EGFRHCK
SCHEMBL31728569 0.67 NQO2 (0.44) PDE5AKDRPIK3CDABL1EGFR
SCHEMBL31728534 0.67 PDE5A (0.44) PDE5AKDRPIK3CDABL1EGFR
SCHEMBL31728048 0.67 PDE5A (0.44) PDE5AKDRPIK3CDABL1EGFR
SCHEMBL31728914 0.67 PDE5A (0.44) PDE5AKDRPIK3CDABL1EGFR
SCHEMBL31727768 0.65 MAP4K4 (0.33) PDE5AKDRLIMK1CDC7PLK4
SCHEMBL31727913 0.64 PDE5A (0.37) PDE5AKDRPIK3CDABL1EGFR
SCHEMBL19877741 0.64 PDE5A (0.44) PDE5AKDRPIK3CDABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback